From 4 to 10 days From 7 to 18 days From 12 to 28 days Modeling suggests tarcocimab may provide a similar immediacy of efficacy while meaningfully extending dosing intervals for all patient types 1 10 100 1000 10000 0 30 60 Ocular Drug Quantity Time (days) Patient with Short Ocular T 1/2 0 30 60 90 120 150 Time (days) Patient with Average Ocular T 1/2 0 30 60 90 120 150 180 210 240 Time (days) Patient with Long Ocular T 1/2 Faricimab Tarcocimab Conjugated Protein Tarcocimab Unconjugated Protein Tarcocimab extends dosing interval from 3-4 weeks to 6-8 weeks Tarcocimab extends dosing interval from 8 weeks to 3+ months Tarcocimab extends dosing interval from 12 weeks to 6+ months Faricimab & Tarcocimab free protein t 1/2 = 7 days Tarcocimab conjugate t 1/2 =18 days Tarcocimab conjugate t 1/2 =10 days Faricimab & Tarcocimab free protein t 1/2 = 4 days TARCOCIMAB Extended T 1/2 FARICIMAB VABYSMO (faricimab solution for injection) Prescribing Information. South San Francisco, USA: Genentech, Inc. PK and ER of Faricimab, Report # 1105763 10-90th percentiles Faricimab & Tarcocimab free protein t 1/2 = 12 days Tarcocimab conjugate t 1/2 =28 days Human Ocular Half-Life (Days) 21